Fungal fingerprints in lungs may predict ABPA Flare-Ups

NCT ID NCT07690345

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study looks at people with allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common fungus. Researchers want to see if having fungus detectable in sputum or lung fluid samples is linked to more frequent flare-ups or worse outcomes. Participants will be followed for 12 months to track exacerbations and changes in immune markers and lung function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If fungal status predicts outcomes, doctors could tailor treatments more precisely for ABPA patients.
What could go wrong
This is an observational study, not a treatment trial. It may not prove cause and effect, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABPA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China

    RECRUITING

    Jinan, Shandong, 250014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.